CN115916984A - 腺病毒表达载体及生产方法和细胞系 - Google Patents

腺病毒表达载体及生产方法和细胞系 Download PDF

Info

Publication number
CN115916984A
CN115916984A CN202180040972.1A CN202180040972A CN115916984A CN 115916984 A CN115916984 A CN 115916984A CN 202180040972 A CN202180040972 A CN 202180040972A CN 115916984 A CN115916984 A CN 115916984A
Authority
CN
China
Prior art keywords
vector
seq
adenoviral
sequence
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040972.1A
Other languages
English (en)
Chinese (zh)
Inventor
C·埃克斯莱恩
H·刘
S·史蒂文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lung Biotechnology PBC
Original Assignee
Lung Biotechnology PBC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lung Biotechnology PBC filed Critical Lung Biotechnology PBC
Publication of CN115916984A publication Critical patent/CN115916984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202180040972.1A 2020-04-07 2021-04-06 腺病毒表达载体及生产方法和细胞系 Pending CN115916984A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006266P 2020-04-07 2020-04-07
US63/006,266 2020-04-07
PCT/US2021/025890 WO2021207136A1 (en) 2020-04-07 2021-04-06 Adenoviral expression vector and methods and cell lines for production

Publications (1)

Publication Number Publication Date
CN115916984A true CN115916984A (zh) 2023-04-04

Family

ID=75660398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180040972.1A Pending CN115916984A (zh) 2020-04-07 2021-04-06 腺病毒表达载体及生产方法和细胞系

Country Status (9)

Country Link
US (2) US12227754B2 (https=)
EP (1) EP4133090A1 (https=)
JP (2) JP7750858B2 (https=)
KR (1) KR20230008069A (https=)
CN (1) CN115916984A (https=)
AU (1) AU2021251718A1 (https=)
CA (1) CA3174985A1 (https=)
IL (1) IL297178A (https=)
WO (1) WO2021207136A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250091839A (ko) 2023-12-14 2025-06-23 김현우 강판의 부식방지용 페인트 자동 제거장치
WO2025160234A1 (en) * 2024-01-26 2025-07-31 Cystic Fibrosis Foundation Cftr super exon constructs and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1258740A (zh) * 1998-12-31 2000-07-05 上海华晨生物技术研究所 表达人白细胞介素12的重组腺病毒及其制法和用途
US20060270041A1 (en) * 2004-12-13 2006-11-30 Howe John A Cell lines for production of replication-defective adenovirus
CN1972958A (zh) * 2004-04-12 2007-05-30 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
US20080044378A1 (en) * 2006-05-15 2008-02-21 Introgen Therapeutics, Inc. Methods and Compositions for Protein Production Using Adenoviral Vectors
CN103966263A (zh) * 2013-02-04 2014-08-06 广州医学院第一附属医院 一种重组人3型腺病毒及其制备方法和应用
US20140248305A1 (en) * 2013-03-01 2014-09-04 The Wistar Institute Adenoviral vectors comprising partial deletions of e3
US20180171305A1 (en) * 2016-12-20 2018-06-21 Salk Institute For Biological Studies Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses
CN110300597A (zh) * 2016-12-09 2019-10-01 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
WO2005012537A2 (en) 2003-07-25 2005-02-10 Genvec, Inc. Adenoviral vector-based vaccines
CN111356763B (zh) 2017-09-22 2024-03-12 建新公司 变体RNAi
CN112292449A (zh) * 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1258740A (zh) * 1998-12-31 2000-07-05 上海华晨生物技术研究所 表达人白细胞介素12的重组腺病毒及其制法和用途
CN1972958A (zh) * 2004-04-12 2007-05-30 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
US20060270041A1 (en) * 2004-12-13 2006-11-30 Howe John A Cell lines for production of replication-defective adenovirus
CN101208425A (zh) * 2004-12-13 2008-06-25 坎吉有限公司 产生复制缺陷型腺病毒的细胞系
US20080044378A1 (en) * 2006-05-15 2008-02-21 Introgen Therapeutics, Inc. Methods and Compositions for Protein Production Using Adenoviral Vectors
CN103966263A (zh) * 2013-02-04 2014-08-06 广州医学院第一附属医院 一种重组人3型腺病毒及其制备方法和应用
US20140248305A1 (en) * 2013-03-01 2014-09-04 The Wistar Institute Adenoviral vectors comprising partial deletions of e3
CN110300597A (zh) * 2016-12-09 2019-10-01 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
US20180171305A1 (en) * 2016-12-20 2018-06-21 Salk Institute For Biological Studies Use of phospholipid scramblase inhibitors for modulating inflammatory immune responses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DELPHINE REA等: "Recombinant Adenovirus-Transduced Human Dendritic Cells Engineered to Secrete Interleukin-10 (IL-10) Suppress Th1-Type Responses While Selectively Activating IL-10 –Producing CD4 T Cells", HUMAN IMMUNOLOGY, vol. 65, no. 11, 1 November 2004 (2004-11-01), XP004647127, DOI: 10.1016/j.humimm.2004.08.185 *
SUGARMAN, B.J.等: "Human adenovirus C serotype 5, complete genome", GENBANK, 13 August 2007 (2007-08-13), pages 339865 *
WILLIAM SM WOLD等: "Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy", CURRENT GENE THERAPY, vol. 13, no. 6, 4 September 2014 (2014-09-04), pages 421 - 433, XP055824116, DOI: 10.2174/1566523213666131125095046 *

Also Published As

Publication number Publication date
US12227754B2 (en) 2025-02-18
KR20230008069A (ko) 2023-01-13
US20210310025A1 (en) 2021-10-07
WO2021207136A1 (en) 2021-10-14
US20250137013A1 (en) 2025-05-01
JP7750858B2 (ja) 2025-10-07
EP4133090A1 (en) 2023-02-15
IL297178A (en) 2022-12-01
AU2021251718A1 (en) 2022-11-10
JP2023521149A (ja) 2023-05-23
JP2025175172A (ja) 2025-11-28
CA3174985A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP7347933B2 (ja) 血友病ａ治療に対する遺伝子療法
CN106459932B (zh) 高胆红素血症的治疗
CN107864653B (zh) 衣壳
KR102063483B1 (ko) Ａａｖ 캡시드 변이체를 이용한 고효율 유전자 전달을 위한 조성물 및 방법
EP2675484B1 (en) Improved aav8 vector with enhanced functional activity and methods of use thereof
US20170007720A1 (en) Methods and compositions for gene delivery to on bipolar cells
US20250137013A1 (en) Adenoviral expression vector and methods and cell lines for production
CN110914419A (zh) 糖原贮积病iii的治疗
US20230323390A1 (en) Methods and compositions for expressing phenylalanine hydroxylase
WO2021108468A1 (en) Novel aav3b variants that target human hepatocytes in the liver of humanized mice
CN113747926A (zh) 用于肌肉表达的杂合启动子
TW202229315A (zh) 改良的腺相關病毒(aav)載體及其用途
JP2023509443A (ja) 改善されたａａｖ－ａｂｃｄ１コンストラクトならびに副腎白質ジストロフィー（ａｌｄ）および／または副腎脊髄ニューロパチー（ａｍｎ）の処置または予防のための使用
CN111718418A (zh) 一种增强基因编辑的融合蛋白及其应用
US20220389450A1 (en) Vector system
KR20230091788A (ko) 폐 세포 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터
CN115087738A (zh) 用于穿越人血脑屏障的腺相关病毒载体
WO2026072721A1 (en) Parvovirus compositions and methods for gene therapy
EP4570260A1 (en) Viral vector for transduction of adipocytes
EP4089171A1 (en) Recombinant tert-encoding viral genomes and vectors
WO2025113432A1 (zh) 一种用于治疗x染色体连锁视网膜劈裂症的基因药物
WO2026052057A1 (zh) 核酸组合及其用途
CN115948403A (zh) 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用
AU2024295314A1 (en) Vector constructs for delivery of nucleic acids encoding uricase and methods of using the same
CN120400250A (zh) 表达myo7a蛋白的双载体系统及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination